Eli Lilly and Novo Nordisk to maintain 'two-horse race' in GLP-1 weight loss market
U.Ozel.Images/E+ via Getty Images Although other companies are on the cusp of gaining approval for GLP-1 receptor agonist weight-loss drugs, ...
Tag: Lilly
Deutsche Bank rates Eli Lilly as a “high-growth unicorn” and upgrades its rating to Buy (NYSE:LLY)
Eli Lilly (New York Stock Exchange:LLY) was in the spotlight on Monday after Deutsche Bank raised its rating on the ...
Eli Lilly and Novo extend their declines for several days in an unusual wave of sales (NYSE:LLY)
alexsl/E+ via Getty Images Shares of weight loss drug company Eli Lilly (New York Stock Exchange:LLY) and Novo Nordisk (NVO) ...
ResMed cuts Oppenheimer after Lilly sleep apnea data
Pgiam/iStock via Getty Images Oppenheimer downgraded respiratory device maker ResMed (New York Stock Exchange: RMD) outperformed on Tuesday, citing an ...
Analysts Reveal Eli Lilly Stock Price Targets After Earnings
The people of Eli Lilly (LYLY) They say they are working as fast as they can.The drugmaker, which reported its ...
Weight-loss drug prompts Eli Lilly to raise 2024 sales forecast by $2 billion By Reuters
By Bhanvi Satija and Patrick Wingrove(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's (NYSE:) weight-loss drug Zepbound led ...
Eli Lilly to add $4.1 billion in sales thanks to anti-obesity drug Zepbound
hapabapa/iStock Editorial via Getty Images Eli Lilly's Sales (New York Stock Exchange:LLY) recently approved weight-loss drug Zepbound could reach $4.1 ...
US FDA approves Lilly weight loss drug and will compete with Wegovy de Novo By Reuters
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing facility at 50 ImClone Drive in Branchburg, New Jersey, ...
Eli Lilly slumps after cutting profit outlook despite rising weight-loss drug profits
Eli LillyLYLYIt posted better-than-expected third-quarter earnings on Thursday thanks to continued growth in sales of its anti-obesity drug Mounjaro, which ...
Eli Lilly Named Gilead Favorite at BofA Ahead of Q3 Earnings
in focus Heading into the biopharmaceutical sector's third-quarter earnings season, Bank of America has taken a bullish stance on Eli ...
Recommended.
